Furthermore, the use of pyrotinib together with radiotherapy can significantly improve the PFS, ORR, and duration of response in patients with HER2-positive breast cancer brain metastases without causing serious AEs (Tian et al., 2022). Here, ERBB2 is linked to breast cancer.